Displaying drugs 7501 - 7525 of 8282 in total
YS-ON-001
YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Investigational
Matched Description: … YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly …
TPIV 200
TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Investigational
Matched Description: … TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage …
Autogene cevumeran
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Investigational
Matched Description: … Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated …
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
Matched Description: … RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene …
AAV-dXIAP
AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Investigational
Matched Description: … AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis …
DCN-tCRK
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
Matched Description: … DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal …
Allitinib
Allitinib is under investigation in clinical trial NCT04671303 (To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer).
Investigational
Matched Description: … Allitinib is under investigation in clinical trial NCT04671303 (To Evaluate the Efficacy and Safety of …
Depemokimab
Depemokimab is under investigation in clinical trial NCT05274750 (Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps).
Investigational
Matched Description: … Depemokimab is under investigation in clinical trial NCT05274750 (Efficacy and Safety of Depemokimab …
Etigilimab
Etigilimab is under investigation in clinical trial NCT04761198 (A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.).
Investigational
Matched Description: … Etigilimab is under investigation in clinical trial NCT04761198 (A Study of Etigilimab and Nivolumab …
Imlunestrant
Imlunestrant is under investigation in clinical trial NCT05514054 (A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer).
Investigational
Matched Description: … Imlunestrant is under investigation in clinical trial NCT05514054 (A Study of Imlunestrant Versus Standard …
Bemnifosbuvir
Bemnifosbuvir is under investigation in clinical trial NCT05629962 (SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-risk Outpatients With COVID-19).
Investigational
Matched Description: … Bemnifosbuvir is under investigation in clinical trial NCT05629962 (SUNRISE-3: Efficacy and Safety of …
Aklavine
Aklavine is under investigation in clinical trial NCT03026842 (Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With T(8;21)).
Investigational
Matched Description: … in clinical trial NCT03026842 (Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of …
Isuzinaxib
Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).
Investigational
Matched Description: … Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced …
Pyrrolizidine
Pyrrolizidine is under investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC).
Investigational
Matched Description: … investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of …
YSIL6
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
CR002
CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to treat kidney inflammation.
Investigational
Matched Description: … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived …
Ranirestat
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
Investigational
Matched Description: … It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy …
PRO-542
PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Investigational
Matched Description: … PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from …
CCR5 mAb
CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). It was generated by HGS using the Abgenix XenoMouse technology.
Investigational
Matched Description: … specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of …
Zastumotide
Zastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
Investigational
Matched Description: … investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of …
Pateclizumab
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of …
Efinopegdutide
Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).
Investigational
Matched Description: … Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of …
GX-19 Vaccine
The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea . As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Investigational
Matched Description: … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels …
Gavocabtagene autoleucel
Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
Investigational
Matched Description: … Gavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of …
Displaying drugs 7501 - 7525 of 8282 in total